후외측 요추 유합술을 받는 환자에서 자가 이식편과 비교한 MagnetOs Putty의 시판 후 연구 (PROOF)
2단계 계측 후외측 요추/흉요추 융합(PLF)을 받는 환자의 자가 이식편과 비교하여 MagnetOs 퍼티의 안전성 및 성능을 평가하기 위한 전향적, 무작위, 단일 센터 연구
This is a phase IV post-marketing study for MagnetOs Easypack Putty. MagnetOs Easypack Putty is a synthetic bone graft extender product that is routinely used by surgeons as a treatment for patients with degenerative disc disease or spinal trauma undergoing spinal fusion surgery.
In this study, MagnetOs Easypack Putty will be used according to the latest U.S. Instructions For Use, standalone in the posterolateral spine.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
In this study, following a screening period of a maximum of 30 days, 60 patients will undergo up to two-level instrumented posterolateral fusion (PLF) procedure. Prior to surgery, each patient will be randomized to receive MagnetOs Easypack Putty standalone on the assigned side of the spine and Demineralized Bone Matrix or Fibers mixed with local autograft bone on the other at the diseased levels. They will be followed up at discharge, Week 2, Month 3, Month 6, and Month 12. An interim analysis will be performed once 30 patients have completed their Month 6 visit and have measurements for the endpoints available to measure effectiveness. The primary endpoint will be analyzed at Month 12.
In this study, MagnetOs Easypack Putty will be applied according to the latest Instructions for Use approved in the United States. Specifically, MagnetOs Easypack Putty will be used standalone in patients up to two-level degenerative disc disease with segmental mechanical spinal instability requiring treatment with an instrumented posterolateral spine fusion procedure. The fusion procedure (PLF) will be left to the surgeon's discretion.
Radiographs will be obtained at Screening, Discharge, Month 3, Month 6 and Month 12. CT scans will only be obtained at Month 6 and Month 12.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
California
-
Irvine, California, 미국, 92697
- The Regents of the University of California- Irvine Campus
-
-
Michigan
-
Grand Rapids, Michigan, 미국, 49503
- Corewell Health
-
-
Missouri
-
St Louis, Missouri, 미국, 63130
- The Washington University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, 미국, 19107
- Rothman Orthopaedic Institute
-
-
Tennessee
-
Nashville, Tennessee, 미국, 37209
- Tennessee Orthopaedic Alliance
-
-
Washington
-
Seattle, Washington, 미국, 98104
- University of Washington
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Patient is able to read/be read, understand, and provide written informed consent and has signed the Institutional Review Board (IRB) approved informed consent.
- Male or female patient ≥ 18 years old.
- Patients with segmental mechanical spinal instability requiring arthrodesis surgery.
Instability can be either caused by degenerative disc disease or by traumatic injury to the spinal column. Patient requiring a maximum of two-level instrumented posterolateral lumbar/thoraco-lumbar fusion (T11 - S1) will be enrolled. Mechanical instability is defined by the presence of one or more of the following:
-
instability (angulation ≥ 5 degrees or translation ≥ 3 mm on flexion/extension radiographs),
-
decreased disc height by > 2 mm, but dependent upon the spinal level
-
Grade II or more listhesis
-
TLICS equal or greater than 5
-
Unstable burst fracture
- Failed conservative treatment (physical therapy, bed rest, medications, spinal injections, manipulations, or transcutaneous electrical nerve stimulation) for a minimum period of 3 months prior to study enrollment (if the patient undergoes elective surgery). Patients who have spinal instability (as defined above in inclusion criteria number three), caused by acute trauma requiring urgent surgical treatment are excluded from this criterion.
Exclusion Criteria:
- Requires > two-level fusion or expected to need secondary intervention within one year following surgery.
- Had prior PLF fusion or attempted PLF fusion at the involved levels.
- Had previous decompression at the involved levels.
- Women who are or intend to become pregnant within the next 12 months.
- To treat conditions in which general bone grafting is not advisable.
- In conditions where the surgical site may be subjected to excessive impact or stresses, including those beyond the load strength of fixation hardware (e.g. defect site stabilization is not possible).
- In case of significant vascular impairment proximal to the graft site.
- In case of severe metabolic or systemic bone disorders (e.g., osteogenesis imperfecta, history of or active Pott's disease, stage >4 renal disease or Paget's Disease) that affect bone or wound healing.
- In case of acute and chronic infections in the operated area (soft tissue infections; inflammation, bacterial bone diseases; osteomyelitis).
- When intraoperative soft tissue coverage is not planned or possible.
- Receiving treatment with medication interfering with calcium metabolism.
- Has degenerative disc disease (DDD) related to a benign or malignant tumor.
- Has history or presence of active malignancy.
- Has known substance abuse, psychiatric disorder, or a condition which, in the opinion of the investigator, may influence the healing or ability to comply with protocol requirements.
- Is involved in active litigation relating to his/her spinal condition.
- Has participated in an investigational study within 30 days prior to surgery for study devices.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: MagnetOs Easypack Putty
Interventions
|
MagnetOs Easypack Putty used standalone in instrumented posterolateral fusion, 5cc-15c per spine level at the randomized assigned side. |
|
활성 비교기: Demineralized Bone Matrix or Fibers (DBX or Grafton) mixed with local autograft bone
Interventions
|
Demineralized Bone Matrix or Fibers (DBX or Grafton) mixed in a 1:1 vol% with local autologous bone graft used in instrumented posterolateral fusion, 5cc-15cc per level mixed with bone marrow aspirate/blood per spine level at the contralateral side. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Radiographic Fusion by CT Scan
기간: Month 12
|
The rate of posterolateral lumbar/thoracolumbar fusion assessed by CT-scan at Month 12. Radiographic as determined by evidence of bridging trabeculae or continuous bony connection between the superior and inferior transverse processes. |
Month 12
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Radiographic Fusion by Plain Radiographs
기간: Month 6, Month 12
|
The rate of posterolateral lumbar/thoracolumbar fusion assessed by plain radiographs. |
Month 6, Month 12
|
|
Radiographic Fusion by CT Scan
기간: Month 6
|
The rate of posterolateral lumbar/thoracolumbar fusion assessed by CT-scan at Month 6. Radiographic as determined by evidence of bridging trabeculae or continuous bony connection between the superior and inferior transverse processes. |
Month 6
|
|
Functional Outcome by Oswestry Disability Index Questionnaire
기간: Screening, Week 2, Month 3, 6, and 12
|
Functional outcome by the Oswestry Disability Index questionnaire. Patient-completed questionnaire which gives a subjective percentage score of level of function (disability) in activities of daily living in those rehabilitating from low back pain. The lower the percentage the higher the patient's functionality. 0-20% minimal disability, 80-100% significant disability or bedridden. |
Screening, Week 2, Month 3, 6, and 12
|
|
Back and Leg Pain by Visual Analog Pain Scale Questionnaire
기간: Screening, Week 2, Month 3, 6, and 12
|
Change in back and leg pain using Visual Analog Pain Scale (0-100). Patient-completed questionnaire scoring pain by using 100 mm line. Zero being no pain, 100 is worst pain imaginable. |
Screening, Week 2, Month 3, 6, and 12
|
|
Neurologic Status by Physical Exam
기간: Screening, Week 2, Month 3, 6, and 12
|
Change in neurologic status by examination to document stable, improved, or deficits in condition. Stable or improved findings for lower extremities, specifically reflexes, muscle strength, sensory, and straight leg raise. |
Screening, Week 2, Month 3, 6, and 12
|
|
Success Rate
기간: Week 2, Month 3, 6, and 12
|
Number of patients with secondary surgical interventions (SSI's) such as revisions, re-operations, removals, supplemental fixations, or any other procedure that adjusts or removes part of the original implant configuration with or without replacement of the components within 12 months of surgery. |
Week 2, Month 3, 6, and 12
|
기타 결과 측정
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Safety Endpoint - number of patients with Adverse Events
기간: 12 Months
|
The number of patients with Adverse Events from Screening up to Month 12 after surgery. |
12 Months
|
|
Safety Endpoint - number of patients with Serious Adverse Events
기간: 12 Months
|
The number of patients with Serious Adverse Events from Screening up to Month 12 after surgery |
12 Months
|
|
Safety Endpoint - number of patients with Adverse Device Effects
기간: 12 Months
|
The number of patients with Adverse Device Effects from Screening up to Month 12 after surgery. |
12 Months
|
|
Safety Endpoint - number of patients with Device Related Complications
기간: 12 Months
|
The number of patients with any complications considered to device related with 12 months after surgery. |
12 Months
|
|
Health Economic - Duration of Surgery
기간: 12 Months
|
Duration of surgery in minutes. |
12 Months
|
|
Health Economic - Duration of Hospitalization
기간: 12 Months
|
Duration of hospital stay in days. |
12 Months
|
|
Health Economic - Return to Work
기간: 12 Months
|
Time to return to work in days. |
12 Months
|
공동 작업자 및 조사자
협력자
협력자
수사관
수사관
- 연구 책임자: Cesar Silva, MD, Kuros BioSciences B.V.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
기타 연구 ID 번호
기타 연구 ID 번호
- MAG-920-023
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .